RNA
Avidity Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
RNA Profile
Avidity Biosciences, Inc.
A biotech company developing oligonucleotide-based therapies for rare genetic disorders
Biological Technology
11/13/2012
06/12/2020
NASDAQ Stock Exchange
391
12-31
Common stock
10578 Science Center Drive, Suite 125, San Diego, CA 92121
--
Avidity Biosciences, Inc., was incorporated under the laws of the State of Delaware on November 13, 2012. The company is a biopharmaceutical company. The Company has pioneered a new class of oligonucleotide-based therapies, called antibody oligonucleotide conjugates (AOCs), designed to overcome the current limitations of oligonucleotide therapies to treat a variety of serious diseases. The company utilizes its proprietary AOC platform to design, plan and develop therapies that combine the precision of monoclonal antibodies (mAbs) with tissue-selective and oligonucleotide therapies to access previously unabsorbable tissue and cell types and more effectively target the underlying genetic drivers of the disease.